降尿酸治疗对痛风高尿酸血症患者IL-1β和NALP3水平的影响

Influence of Uric Acid-Lowering Therapy on IL-1β and NALP3 Levels in Gout Patients with Hyperuricemia

目的观察黄嘌呤氧化酶抑制剂对痛风高尿酸血症患者体内炎症因子水平的影响。方法将72例痛风高尿酸血症患者按治疗方法的不同分为3组,分别给予非布司他40 mg·d^(-1)、80 mg·d^(-1)、别嘌呤醇300 mg·d^(-1)治疗6个月;另选24例健康受试者作为对照组。所有受试者治疗前后进行血尿酸检测,采用ELISA法进行血清白介素-1β(IL-1β)和核苷酸结合寡聚化结构域样受体3(NALP3)水平检测。结果治疗前痛风治疗组血尿酸水平明显高于对照组,药物治疗6个月后血尿酸水平明显降低。治疗前痛风治疗组血清IL-1β水平高于对照组,药物治疗后血清IL-1β水平有所下降;治疗前痛风治疗组血清NALP3水平低于对照组,药物治疗后血清IL-1β水平有所上升。结论黄嘌呤氧化酶抑制剂能明显降低这类患者血尿酸水平,降尿酸治疗可能存在下调体内炎症反应的趋势。

Objective To observe the influence of xanthine oxidase inhibitors on the levels of inflammatory factors in gout patients with hyperuricemia.Methods Seventy-two gout patients with hyperuricemia were treated with febuxostat 40 mg·d-1 ,febuxostat 80 mg·d-1 or allopuri-nol 300 mg·d-1 for 6 months.In addition,24 healthy subjects were selected as the control group. Blood uric acid levels were detected before and after treatment.Furthermore,serum IL-1β and NALP3 levels were measured by ELISA.Results Before treatment,gout patients with hyperuri-cemia had higher levels of uric acid and IL-1βand lower levels of NALP3 than healthy subjects. However,levels of uric acid and IL-1βwere decreased and levels of NALP3 were increased in pa-tients after treatment for 6 months.Conclusion Xanthine oxidase inhibitors can significantly de-crease uric acid levels in gout patients.Uric acid-lowering therapy may show a trend of reducing inflammatory reactions.